arrow
F

Felicetto Ferrara

Cardarelli Hospital
H指数:54
被引数:1.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Allogeneic stem cell transplantation in adult Ph-like acute lymphoblastic leukemia. Results from two consecutive GIMEMA protocols
2026-07-080
OA
Early Ibrutinib Dose Modifications in CLL: A Post Hoc Analysis of the Real-World EVIdeNCE Study

早期伊布替尼剂量调整在CLL中的应用:EVIdeNCE真实世界研究的回顾性分析

Cancers
IF4.4
2026-04-030
OAAI
Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.

根据SIE/SIES/GITMO标准对治疗相关和aml-mrc接受CPX-351的适应性分类的影响。

2025-12-110
OAAI
Venetoclax plus hypomethylating agents as effective bridge therapy to allogeneic stem cell transplant in relapsed/refractory acute myeloid leukaemia: A subanalysis of the AVALON study

Venetoclax联合去甲基化药物作为异基因干细胞移植治疗复发/难治性急性髓系白血病的有效桥梁疗法:AVALON研究的一项亚组分析

2025-11-010
OAAI
Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia

真实世界多中心分析CPX-351在60岁以下继发性急性髓系白血病患者中的疗效

2025-10-260
OA
Real World Study on the Best CPX-351 Treatment Duration and Timing for Allogeneic Stem Cell Transplantation

真实世界研究:异基因干细胞移植的最佳CPX-351治疗时长与时机

2025-09-240
OAAI
Pegaspargase administration and tolerability in patients aged 55 years or older with acute lymphoblastic leukemia treated with the LAL1913 program. A subanalysis of the Campus ALL group

培门冬酶(Pegaspargase)在55岁及以上急性淋巴细胞白血病患者的给药方案与耐受性研究:LAL1913方案的子分析,Campus ALL研究组。

2025-08-270
OAAI
Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia: Observational Study of 673 Patients in Italy

酪氨酸激酶抑制剂在慢性髓性白血病中的停药:意大利673例患者的观察性研究

BLOOD
IF23.1
2024-11-050
PRE
Treatment-Free Remission in CML Patients Discontinuing Post-First Line Therapy

停用一线治疗后慢性粒细胞白血病患者中的无治疗缓解

BLOOD
IF23.1
2024-11-050
PRE
Long-term survival can be achieved in a significant fraction of older patients with core-binding factor acute myeloid leukemia treated with intensive chemotherapy
2024-10-102
OAAI
Outcome of 421 adult patients with Philadelphia-negative acute lymphoblastic leukemia treated under an intensive program inspired by the GIMEMA LAL1913 clinical trial: a Campus ALL study
2024-08-152
OAAI
Feijoa sellowiana derived natural Flavone exerts anti-cancer action displaying HDAC inhibitory activities (vol 39, pg 1902, 2007)
2024-08-010
PRE
Safety of Subcutaneous Daratumumab in Anti-CD38 Monoclonal Antibody-Naive Patients with Plasma Cell Disorders: A Multicenter Real-Life Experience
2023-09-253
OAAI